MARC details
000 -LEADER |
fixed length control field |
03330nam a22003737a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
220706s20222022 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2666-6677 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1016/j.ajpc.2022.100345 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
PMC9097618 [pmc] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
S2666-6677(22)00029-0 [pii] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
35574517 |
245 ## - TITLE STATEMENT |
Title |
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. |
251 ## - Source |
Source |
American Journal Of Preventive Cardiology. 10:100345, 2022 Jun. |
252 ## - Abbreviated Source |
Abbreviated source |
Am J Prev Cardiol. 10:100345, 2022 Jun. |
253 ## - Journal Name |
Journal name |
American journal of preventive cardiology |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Publication date |
2022 Jun |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
epublish |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Medline status |
PubMed-not-MEDLINE |
266 ## - Date added to catalog |
Date added to catalog |
2022-07-06 |
520 ## - SUMMARY, ETC. |
Abstract |
Conclusions: Treating all REDUCE-IT eligible US adults has substantial medication costs but could prevent a substantial number of ASCVD events and associated direct costs. Indirect cost savings by preventing events could outweigh much of the incurred direct costs. Copyright © 2022 The Author(s). |
520 ## - SUMMARY, ETC. |
Abstract |
Methods: We derived REDUCE-IT eligible cohorts in (1) the National Health and Nutrition Examination Surveys (NHANES) 2009-2014 and (2) the Optum Research Database (ORD). Population sizes were obtained from NHANES and observed first event rates (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, or coronary revascularization) were estimated from the ORD. Hazard ratios from REDUCE-IT USA estimated events prevented with IPE therapy. The National Inpatient Sample estimated event costs (facility and professional) and daily IPE treatment cost was approximated at |
-- |
.59. |
520 ## - SUMMARY, ETC. |
Abstract |
Objective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; and (2) medication costs. |
520 ## - SUMMARY, ETC. |
Abstract |
Results: We estimate 3.6 million US adults to be REDUCE-IT eligible, and the observed five-year first event rate without IPE of 19.0% (95% confidence interval [CI] 16.6%-19.5%) could be lowered to 13.1% (95% CI 12.8%-13.5%) with five years of IPE treatment, preventing 212,000 (uncertainty range 163,000-262,000) events. We projected the annual IPE treatment cost for all eligible persons to be |
Linkage |
.0 billion (95% CI |
-- |
.7- |
-- |
.5 billion), but saving |
-- |
.8 billion annually due to first events prevented (net annual cost |
-- |
.3 billion). The total five-year event rate (first and recurrent) could be reduced from 42.5% (95% CI 39.6%-45.4%) to 28.9% (95% CI 26.9-30.9%) with five years of IPE therapy, preventing 490,000 (uncertainty range 370,000-609,000) events (net annual cost |
Source |
.6 billion). |
546 ## - LANGUAGE NOTE |
Language note |
English |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Health Research Institute |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Weintraub, William S |
790 ## - Authors |
All authors |
Abrahamson D, Andrade KE, Bhatt DL, Bress AP, Derington CG, Fan W, Herrick JS, Jiao L, Johnson J, Philip S, Weintraub WS, Wong ND |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.ajpc.2022.100345">https://dx.doi.org/10.1016/j.ajpc.2022.100345</a> |
Public note |
https://dx.doi.org/10.1016/j.ajpc.2022.100345 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |